Adage Capital Partners
TXG icon

Adage Capital Partners’s 10x Genomics TXG Stock Holding History

Adage Capital Partners’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-150,000
Closed -$8.39M – 952
2023
Q4 		$8.39M Sell
150,000
-235,116
-61% -$10.2M 0.02% 618
2023
Q3 		$15.9M Hold
385,116
– – 0.04% 459
2023
Q2 		$21.5M Sell
385,116
-178,509
-32% -$9.66M 0.05% 386
2023
Q1 		$31.4M Buy
563,625
+69,509
+14% +$3.25M 0.07% 314
2022
Q4 		$18M Buy
+494,116
New +$16.2M 0.04% 469
2019
Q4 		– Sell
-150,000
Closed -$7.56M – 761
2019
Q3 		$7.56M Buy
+150,000
New +$8.3M 0.02% 574

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Adage Capital Partners's TXG Position: Q1 2024 in Review

Adage Capital Partners sold out of 10x Genomics (TXG) in Q1 2024, closing a stake of 150,000 shares — an estimated $8.39M sold.

Adage Capital Partners first reported a position in TXG in Q3 2019 and held it in 6 quarters. The position peaked at $31.4M in Q1 2023. 290 funds tracked by Wall St. Rank hold TXG as of Q1 2024.

  • Adage Capital Partners reported no remaining 10x Genomics position as of Q1 2024 after selling out during the quarter.
  • Adage Capital Partners sold 150,000 10x Genomics shares in Q1 2024, an estimated $8.39M.
  • Adage Capital Partners first reported a position in 10x Genomics in Q3 2019 and held it in 6 quarters.
  • Adage Capital Partners's 10x Genomics position peaked at $31.4M in Q1 2023.
  • 290 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2024.

Based on Adage Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.